Hemopatch Performance Evaluation: A Prospective Observational Registry

CompletedOBSERVATIONAL
Enrollment

621

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

January 28, 2019

Study Completion Date

January 28, 2019

Conditions
Dura Mater Nick Cut or TearHemostatisAir LeakageBody Fluid Leakage
Interventions
DEVICE

Hemopatch

Patients received product at the discretion of their surgeon.

Trial Locations (15)

6020

Innsbruck Universitaetsklinik, Innsbruck

8035

Hospital de Vall d'Hebrón, Barcelona

13353

Deutsches Herzzentrum Berlin, Berlin

14059

Thomayerova Nemocnice, Prague

17007

Hospital Universitari de Girona Doctor Josep Trueta, Girona

20099

ASKLEPIOS Klinik St. Georg, Hamburg

28007

Hospital General Universitario Gregorio Marañón, Madrid

28046

Hospital La Paz, Madrid

41013

Hospital Universitario Virgen del Rocio, Seville

46063

Krajská Nemocnice Liberec, Liberec

50134

Azienda Ospedaliero-Universitaria Careggi, Florence

65691

Fakultní nemocnice u sv. Anny v Brně, Brno

70852

Fakultní Nemocnice Ostrava, Ostrava

93042

Universitaetsklinikum Regensburg, Regensburg

Unknown

Marien-Krankenhaus Bergisch Gladbach, Bergisch Gladbach

All Listed Sponsors
lead

Baxter Healthcare Corporation

INDUSTRY

NCT03392662 - Hemopatch Performance Evaluation: A Prospective Observational Registry | Biotech Hunter | Biotech Hunter